• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Amorphous Solid Dispersions for Bioavailability Enhancement

    Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success

    Manufacturing Dietary Supplements in Economic Uncertainty

    2023 Contract Manufacturing Survey

    New Possibilities for Small Batch Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories

    Vantage Nutrition Acquires ComboCap

    Secarna, SciNeuro Enter Research Agreement for CNS Diseases

    BioNTech Revenues Slide with Waning Demand for COVID-19 Vaccines

    Codiak BioSciences to File for Chapter 11
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    PharmaBlock Opens New R&D Facility in Pennsylvania

    Macfarlan Smith Annan Facility Marked for Closure  

    Northwest Bio, Advent BioServices Gain MHRA License for Commercial Manufacturing

    Willow, Suanfarma Complete Manufacturing Process for Cannabigerol

    Harm Reduction Therapeutics, Catalent Ink Naloxone Commercial Supply Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Adare Pharma Solutions Chooses Vantage to Lead Packaging Facility Upgrade

    This is Sofgen Pharmaceuticals

    Why Sofgen Pharmaceuticals?

    Stevanato, Recipharm Partner to Develop Pre-fillable Syringes for Soft Mist Inhaler

    Chewgels™ - An Explosive Experience with Innovative Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories

    Secarna, SciNeuro Enter Research Agreement for CNS Diseases

    Pharming Gets FDA Nod for Joenja

    PharmaBlock Opens New R&D Facility in Pennsylvania

    Catalent Licenses Formulation Technology to Deliver High-Concentration Biologics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Grand River Aseptic Manufacturing Receives Zero Observations from FDA Inspection

    Sofgen's Center for Pharmaceutical Excellence (CPhE)

    Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success

    What Does the Future of Gene Therapy Hold?

    Automated Regulatory Electronic Publishing: How is It Changing the Industry?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    U.S. Pharmacopeia (USP)

    Syngene International Ltd.

    Lannett CDMO

    Alcami

    Societal CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    U.S. Pharmacopeia (USP)

    Syngene International Ltd.

    Lannett CDMO

    Alcami

    Societal CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Times, They Are a-Changin’

    For contract organizations and generics, for sure

    The Times, They Are a-Changin’
    Emil W. Ciurczak, DoraMaxx Consulting07.20.18
    I have already dedicated several columns to the technical and financial aspects of modernizing client-contract organization relationships. I am always struck by the “Law of Unintended Consequences” (LofUC) and how often it applies to our industry. It can be described as a marriage between a “good news-bad news joke” and Murphy’s Law. For example, in 1983, the EMA (European Medicines Agency) suggested that incoming materials, both active pharmaceutical ingredients (APIs) and excipients, should be qualified for every container, not merely as a combined sample or even √N + 1 (N = number of containers of a particular lot), but all the containers. Clearly, this wasn’t as bad for European companies supplied by rail with large containers. However, in the U.S., we received our materials in many more smaller truck containers. For example, lactose was received in more than 200 bags per batch. Performing USP or EP testing would be prohibitively long and expensive.

    Considering that, in light of the small number of containers in Europe, the Agency didn’t consider that request very burdensome, at least not in Europe. To U.S. companies, it was a huge expense, both in personnel and time spent. Interesting fact: U.S. affiliates of, say, Swiss giants, didn’t make as much income, yet produced more product. The Swiss didn’t have the same anti-trust laws as we did. It was legal, for example for them to “divide up” the continent so as not to have head-to-head competition. Company “A” would sell a sleep aid in Italy and Spain, company “B” would sell a similar product in Germany and France, “C” would have the Benelux countries and Denmark, and so on. In the U.S., direct competition was the norm, so prices had to be competitive, leading to less profit for more product.

    When faced with the massive workload and limited ability to expand personnel and lab space, we turned to what other industries were using, namely food and agriculture. Since USDA (U.S. Dept. of Agriculture) was as regulated as U.S. FDA, I assumed there were reasonable precedents for Near-Infrared Spectroscopy (NIRS) in products consumed by humans.
    Besides the [O=C-N-H] group was essentially the same for Nylon, proteins, and numerous drug substances. The USDA measured water and starch, so did we. And the rest was easy to imagine.

    But, just as Michaelson’s interferometer had to wait for computers to use the centuries-old mathematics of Monsieur Fourier, NIRS—discovered in 1800 and used in agriculture since the 1950s—had to wait for suitable software and hardware. Both occurred in the 1980s and were put to use by the two leading companies of the time: Pacific Scientific (later NIR Systems) and Technicon (later Bran+Leubbe). Qualitative software was developed (H. Mark at Technicon), making the scanning of hundreds of samples in a morning feasible.

    So, commercial NIR was just becoming good enough to be used in the Pharma industry, just when it was most needed. As icing on the cake, secure user passwords and archived data were about to become commonplace, well before 21CFR11 was written. Today, NIR units—both hand-held and riding on carts—are becoming ubiquitous in Pharma warehouses. Speed? Yes, but wait, there’s more. Since NIRS is best used and can only be used for raw materials in a diffuse reflection mode, physical parameters affect the spectra.

    Why is this important for today’s industry? Remember the LofUC? Quite simply, the information that may be gleaned by a few rapid spectral scans used to take days by traditional means: (ang.) particle size, polymorphic form, crystallinity, moisture, and, of course, identity. Since all these parameters are needed for a successful PAT/QbD program, the industry, both initiator and generic, no longer can cry that knowing these BEFORE production is too hard or takes too long. Of course, when one said “rapid” in the late 1980s, they meant rapid versus the hours and days needed to perform “wet” chemistry. A minute or two per sample was lightning fast by comparison. BUT, not fast enough for real-time production.

    One of the barriers to faster, more sensitive instruments was cost. The detectors were either Silicon (Si) for short-range or near-near-IR (400-1100nm) that included the visible range or “normal” NIR of between 1100 and 2500nm, using lead sulfide (PbS) detectors. Interestingly, the NIR range extends to ~3500 or 3600nm, but both the lamps—tungsten-halogen, or wolfram-halogen for the rest of the world—and PbS detectors pretty much stopped measuring at 2500nm. The NIR region was therefore defined, not by theoretical calculation, but by the hardware available at the time.

    A better material was available, namely Indium Gallium Arsenide (InGaAs). It had an extended spectra range and sensitivity and a lower noise component. Sounds great, right? The telecom industry thought so, too. They were, in essence, hoarding whatever supplies could be manufactured for their own uses: long distance and fiber optic communications. The speed and sensitivity made the material excellent for both home and office use as well as long-distance, even trans-continental, lines. The speed of re-emitting signals with extremely low noise made InGaAs perfect for communications and spectroscopy.

    With the industry with far deeper pockets than instrument companies buying every gram they could, the cost to anyone was high. I asked the owner of a NIR instrument company how much a diode array, not even cooled, with InGaAs would cost. He answered, “About $10,000.” So, I asked what they would cost if you bought them in larger lots. His answer: “Still $10,00 apiece.” Then, in the early 1990s there was a telecom deflation, or “crash,” if you prefer, where many companies merged or went out of business. A number of direct consequences arose as a result:
    1. A whole lot of InGaAs for detectors were suddenly available;
    2. The detectors were suddenly far less expensive ($10,000 down to $100); and
    3. A number of suppliers to the industry were without clients.
    Points one and two explain why traditional instruments rapidly became better, but why is point number three important? Well, the choices for the companies who supplied telecom were simple: close down or find a new niche. Some chose the former, packed their tents, and left town. The latter choice was a happy sample of LofUC: these companies took their devices, based on MEMS—”microelectromechanical systems,” or the technology of microscopic devices, particularly those with moving parts, known as micromachines in Japan, or microsystems technology (MST) in Europe—and proceeded in converting them to hand-held spectrometers.

    Yes, they were sometimes “two-hand” held systems and, because of high R&D costs, hardly inexpensive. But, they were battery-powered and portable and the first generation  showing that such devices were possible. These made warehouse inspections much simpler and led to hand-held Raman devices, as well. But, they were not designed for process control. That occurred with a happy coincidence that preceded the PAT (Process Analytical Technologies) Guidance (2002 draft; 2004 final): Pfizer (UK) worked with Zeiss Optics (Switzerland) to develop a rugged NIR instrument that could ride on a bin blender. It had no wires and was battery powered, utilizing fiber optics to “see” into the blender, measuring a scan with every rotation.

    At the time, this 1-3 second scan was sufficient and the time between scans was long enough to allow real-time calculations. This minor break-through allowed for optimization of blending, the first step in enabling PAT as a practical program. Now, we could characterize raw materials and APIs AND follow blending. It was a quick transition to a stationary NIR unit for drying and granulation monitoring, optimizing both steps. The same equipment with fiber optics was then converted to measure coating, in real time in the coating pans. Real-time tablet measurements weren’t there yet, however.

    Another “UC” came out of left field. A company called Spectral Dimensions in Maryland built a wonderfully useful chemical imaging (CI) microscope that showed the components in a sample (e.g., a tablet), where they were, and could quantify each material—excellent for reverse engineering a proprietary formulation, no? It was, sadly, made of expensive components and, in addition to taking several minutes for each sample, it began life at over $150,000. While not adaptable to the process stream, it served to aid in OOS inspections. Eventually, the price escalated to more than $500,000, so production stopped.

    But, seeing the usefulness of CI, VTT, the Technical Research Center of Finland,  developed a dynamic CI device, where the sample or the device needed to move through the length of the sample. This “push-broom” technology was adapted to scanning blister packages, in real time. The latest iteration, produced by Indatech (France), is capable of scanning and evaluating up to 200,000 tablets per hour.

    It’s interesting how seemingly unrelated businesses and technologies have come together to give us affordable PAT/QbD for the masses. In other words, monitoring and controlling solid dosage forms is not just for the “big boys” anymore. Hence the title.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • merck
    • drying
    • fda
    • generics
    Suggested For You
    Trust, but Verify Trust, but Verify
    Drug Product Safety and Security Drug Product Safety and Security
    Too Much of a Good Thing? Too Much of a Good Thing?
    A Potential “Marriage” A Potential “Marriage”
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Leap, Merck KGaA, Pfizer Partner for Cancer Leap, Merck KGaA, Pfizer Partner for Cancer
    01	Pfizer, Inc. 01 Pfizer, Inc.
    Elemental Impurity & Risk Assessment Elemental Impurity & Risk Assessment
    The Final Frontier The Final Frontier
    BioMarin Receives Pfizer Milestone Payments BioMarin Receives Pfizer Milestone Payments
    Schreiner MediPharm Equips Syringes for Pfizer  Schreiner MediPharm Equips Syringes for Pfizer
    Financial Report: Pfizer Financial Report: Pfizer
    We Need to Get Back to Basics We Need to Get Back to Basics
    CPhI NA to Feature Second Women in Leadership Forum CPhI NA to Feature Second Women in Leadership Forum
    Some Changes in Formulation Paradigms Some Changes in Formulation Paradigms

    Related Columns

    • Trust, but Verify

      Trust, but Verify

      Or, R.I.P, CoA.
      Emil W. Ciurczak, DoraMaxx Consulting 09.09.21

    • Analytical Services | Supply Chain
      Drug Product Safety and Security

      Drug Product Safety and Security

      Is it even possible in an elongated supply chain?
      Emil Ciurczak, President, Doramaxx Consulting 07.16.21

    • Analytical Services
      Too Much of a Good Thing?

      Too Much of a Good Thing?

      Watch out for that pendulum!
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.21


    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    Loading, Please Wait..
    Trending
    • Merck KGaA Secures Exclusive Worldwide Rights To Bavencio
    • Codiak BioSciences To File For Chapter 11
    • BioNTech Revenues Slide With Waning Demand For COVID-19 Vaccines
    • How Industry 5.0 Might Benefit Pharmaceutical Manufacturing
    • Jubilant HollisterStier Appoints Chris Preti President
    Breaking News
    • Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories
    • Vantage Nutrition Acquires ComboCap
    • Secarna, SciNeuro Enter Research Agreement for CNS Diseases
    • BioNTech Revenues Slide with Waning Demand for COVID-19 Vaccines
    • Codiak BioSciences to File for Chapter 11
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Amorphous Solid Dispersions for Bioavailability Enhancement
    • Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success
    • Manufacturing Dietary Supplements in Economic Uncertainty
    • 2023 Contract Manufacturing Survey
    • New Possibilities for Small Batch Manufacturing
    • Supply Chain Risk Management
    • 3 Ways Pharma Can Outsmart Talent Challenges in 2023
    • Nutraceutical Dosage Trends: Functional Gummies Offer Alternative to Tablets and Capsules
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Melodea Launches New Plastic-Free Packaging Solution
    GOED and NASC Announce Strategic Partnership
    NPA: ‘Major Victory’ in Colorado After Amendment to Eating Disorder Bill
    Coatings World

    Latest Breaking News From Coatings World

    HOFFMANN MINERAL to Focus on Comprehensive Sustainability Strategy
    HMG and Prodrive Renew Technical Partnership
    Eastern Coatings Show Sets Schedule for Technical Papers
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs FemDx Medsystems' FalloView Device
    FDA Clears NeuroRPM Parkinson's Disease Monitoring Tech
    Vaporox Earns FDA Nod for VHT-200 Wound Care Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Adragos Pharma Acquires Clinigen's Development Unit, Lamda Laboratories
    Vantage Nutrition Acquires ComboCap
    Secarna, SciNeuro Enter Research Agreement for CNS Diseases
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Thread Beauty Expands Cosmetics Line at Target
    The Body Shop Expands its Refill Program in Canada
    Clinique Introduces Digital Retail Concept—Clinique Lab
    Happi

    Latest Breaking News From Happi

    Arbonne Welcomes New Executives
    Total Sales for Naples Soap Company in 2022 Increase 2% Despite Inflation, Supply Chain Issues
    IBA Supports FDA in the MoCRA Rulemaking and Implementation Process
    Ink World

    Latest Breaking News From Ink World

    hubergroup Print Solutions Presents Sustainable Portfolio at PAMEX 2023
    Weekly Recap: Packaging Inks, Toyo Ink Top This Week’s Stories
    Eastern Coatings Show Announces Schedule for Technical Papers
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    eProductivity Software acquires Tharstern Group
    Imageworx details new facility, Avery Dennison tackles recycling and more
    TLMI announces 2022 Eugene Singer Award winners
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Period Care Brand August Launches in Target Stores
    Albany International Announced CEO Succession Plan
    Ahlström Partners to Make Sustainable Butter, Margarine Packaging
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Exactech Boosts AI Expertise with Licensing Deal, Team of Scientists
    Anchor Harvey Celebrates 100th Anniversary in 2023
    Arjun Ishwar Joins Miach Orthopaedics as Sales and Marketing VP
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Honored with Supplier of the Year 2022 Award by Hyundai Motor Group 
    Weekly Recap: Dave Rahami, Zebra, Dracula Technologies Top This Week’s Stories
    Midsummer, UCLA Collaborate on Perovskite-CIGS Tandem Solar Cells

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login